[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 442
Citations 0
Health Agencies Update
December 26, 2012

Challenge to Alzheimer Drug

JAMA. 2012;308(24):2557. doi:10.1001/jama.2012.156122

The US Food and Drug Administration (FDA) is keeping an Alzheimer drug on the market despite concerns about its safety and efficacy.

The agency turned down a petition to remove donepezil 23, a higher-dose (23-mg) version of donepezil, which recently became available as a generic in 5-mg and 10-mg doses. The petition, submitted by Public Citizen in May 2011, argued that the drug does not provide enough benefits to patients to outweigh the increased adverse events associated with it. Of particular concern was an increase in vomiting, which can lead to serious complications in this patient group. Public Citizen filed a lawsuit against the FDA in September after not getting a response from the agency; in November, the agency rejected the petition.

First Page Preview View Large
First page PDF preview
First page PDF preview